← back to search
Dexiu Bu
Novartis (Switzerland) · CH
Area of research
Oncology · Hematology
Research interest
Research interests include Medicine, Cytokine release syndrome, Fludarabine, Internal medicine, and CAR T-cell therapy.
h-index
—
citations
37
works
1
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Journal of Clinical Oncology
2023
cited by
37
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
Jennifer Mataraza
· Novartis (Switzerland)
1
papers (2023–2023)
—
·
1
papers (2023–2023)
—
·
1
papers (2023–2023)
Anita D’Souza
· Medical College of Wisconsin
1
papers (2023–2023)
Nikhil C. Munshi
· Harvard University
1
papers (2023–2023)
—
·
1
papers (2023–2023)
Rao Prabhala
· Harvard University
1
papers (2023–2023)
Andrzej Jakubowiak
· Palmetto Hematology Oncology
1
papers (2023–2023)
Benjamin A. Derman
· Comprehensive Cardiovascular
1
papers (2023–2023)
David Pearson
· Novartis (Switzerland)
1
papers (2023–2023)
David S. Quinn
· AbbVie (United States)
1
papers (2023–2023)
Adam S. Sperling
· Harvard University
1
papers (2023–2023)
—
·
1
papers (2023–2023)
Yifang Li
· Guangzhou University of Chinese Medicine
1
papers (2023–2023)
Serena De Vita
· Harvard Stem Cell Institute
1
papers (2023–2023)
Jessica Liegel
· University of Minnesota, Twin Cities
1
papers (2023–2023)
Sarah Nikiforow
· Harvard University
1
papers (2023–2023)
Jerome Ritz
· Harvard University
1
papers (2023–2023)
—
·
1
papers (2023–2023)